Pharma software development: How to pick a partner

Here's what happens when a pharma company hires a general-purpose software development agency:

Week 1-3: Requirements are clear. The agency understands the functionality. The UX designs look great. Everyone's excited about the 12-week timeline.

Week 4-6: The agency starts building. Code quality is good. Sprint demos show progress. The project feels on track.

Week 7: Someone from the quality assurance department joins a sprint review and asks: "Where are the audit trails? How are you handling electronic signatures? Where's the URS? When do we start IQ/OQ?"

Week 8-12: The project stalls. The agency retrofits audit trails into every database table. Electronic signature workflows get bolted on. They Google "FDA 21 CFR Part 11" for the first time. The URS is written retroactively. The traceability matrix is assembled from scratch.

Week 13-24: Validation documentation. IQ/OQ/PQ protocols. Deviation reports. Re-testing after compliance fixes.

A 12-week project becomes a 24-week project. The budget doubles. The relationship sours.

This is not a hypothetical scenario. This is the most common outcome when pharma companies select technology partners based on portfolio quality and price without evaluating compliance engineering capability.

What makes pharma different

A 2024 Gartner analysis of regulated software projects found that compliance-related rework accounts for 35-45% of total project costs when validation requirements are discovered mid-build rather than designed in from the start. In pharma specifically, where FDA 21 CFR Part 11 and EU Annex 11 apply to any electronic record, the cost of retrofitting compliance can exceed the original development budget.

"The biggest risk in pharma software isn't the technology - it's the regulatory discovery gap. Teams that treat GxP as a technical checkbox rather than an architectural discipline end up rebuilding 40-60% of their system after the quality team gets involved."

• Patricia Hurter, former Vice President of Global Regulatory Affairs at GSK, speaking at the 2023 FDA Software as a Medical Device Workshop

Pharmaceutical software development operates under constraints that don't exist in standard software projects:

The Standish Group's CHAOS research finds that only 31% of software projects are delivered on time, on budget, with required features. In pharma, where compliance adds undiscovered complexity, that number is lower. The most common cause is not poor coding. It's requirements that change shape when the regulatory layer surfaces.

Every system is auditable. Regulatory inspectors from the FDA, EMA, MHRA, CDSCO, and other authorities can request to see any electronic record, its complete change history, the identity of everyone who touched it, and the validation documentation proving the system works as specified. Your development partner needs to build systems that are perpetually audit-ready - not systems that need a 2-week cleanup before an inspection.

Validation is mandatory, not optional. Computer System Validation (CSV) is a regulatory requirement for any software that touches GxP data. It means documentation (URS, FS, DS), qualification protocols (IQ, OQ, PQ), and traceability matrices linking requirements to tests to results. A partner that hasn't produced these deliverables before will underestimate the effort by 40-60%.

Changes require change control. After a GxP system is validated and deployed, bug fixes and feature additions alike must go through a documented change control process. Each change must be assessed for impact, approved by the quality function, implemented with updated validation, and documented. Your development partner's post-launch support model must account for that overhead.

Data integrity isn't optional. The ALCOA+ framework - Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available - governs how data is created, modified, and stored. This isn't an academic framework. Inspectors specifically look for ALCOA+ compliance in electronic systems.

Five criteria for evaluating pharma software partners

The Standish Group CHAOS Report consistently shows only 29-31% of software projects are delivered on time, on budget, and with required features. In regulated industries, the failure rate is higher because compliance adds requirements that surface late. Choosing the right partner from the start is the single most impactful decision in a pharma software project.

1. GxP experience (non-negotiable)

Ask directly: "Have you built software that passed a regulatory audit?" Not "software for a pharma company" - software that was validated and inspected.

The difference matters. A company can build a pharma company's marketing website (no GxP requirements) and truthfully claim pharma experience. That's different from building a training platform, quality management system, or pharmacovigilance database that underwent CSV and withstood regulatory inspection.

What to ask for:

• Sample validation documentation (URS, FS, traceability matrix) - anonymized is fine, the format and rigor are what you're evaluating

• Names of regulatory frameworks they've built for (FDA 21 CFR Part 11, EU Annex 11, GAMP 5)

• Description of how they integrate validation into development sprints

RaftLabs has built GxP-compliant software including a training platform for 4,200 pharma sales reps across 11 countries, with country-specific compliance mapping and full audit trail coverage.

2. Validation documentation capability

The deliverables for a GxP software project include:

• User Requirements Specification (URS)

• Functional Specification (FS)

• Design Specification (DS)

• Traceability Matrix (URS → FS → DS → test cases → results)

• Installation Qualification (IQ) protocol and execution report

• Operational Qualification (OQ) protocol and execution report

• Performance Qualification (PQ) protocol and execution report

• Validation Summary Report

A development partner that can produce code but can't produce these documents is a partner that will need your internal quality team to write the validation documentation - effectively outsourcing the development but not the validation, which defeats the purpose.

What to ask for:

• A sample traceability matrix from a previous project

• Their process for maintaining traceability during agile development

• Who on their team writes validation documentation (if the answer is "we'll figure it out," walk away)

3. Regulated industry track record

GxP is pharma's compliance framework, but the engineering discipline of building auditable, validated systems transfers across regulated industries:

• Healthcare - HIPAA compliance requires audit trails, access controls, and encryption

• Financial services - SOC 2 and PCI DSS require similar security controls and audit capabilities

• Medical devices - IEC 62304 requires software lifecycle documentation comparable to GAMP 5

A development partner with experience across regulated industries - even if not specifically pharma - brings the compliance engineering mindset that's 80% of what pharma requires. The remaining 20% (pharma-specific domain knowledge) is acquirable.

What to ask for:

• Case studies from healthcare, fintech, or medical device projects

• Specific compliance frameworks they've built for

• How they approach compliance as an architectural concern versus an afterthought

4. Domain knowledge (important but acquirable)

Pharma-specific domain knowledge - understanding GxP regulations, the drug development lifecycle, field force operations, pharmacovigilance workflows, and supply chain serialization - reduces discovery time. A partner who understands these areas spends less time learning your business and more time building your product.

But domain knowledge without compliance engineering capability is less valuable than compliance engineering capability without domain knowledge. You can teach a great engineering team about pharma operations in 2-3 weeks. You can't teach validated systems in 2-3 weeks.

What to evaluate:

• Do they understand the difference between GMP, GLP, GCP, and GDP?

• Can they describe what GAMP 5 Category 5 validation requires?

• Do they know what ALCOA+ means without looking it up?

5. Delivery timeline and approach

The single biggest differentiator between pharma software partners is delivery timeline. The traditional approach - build the software, then validate it - produces 6-12 month timelines for projects that should take 3-4 months.

Sprint-integrated validation - the approach RaftLabs uses - produces 12-16 week timelines for the same scope because validation runs alongside development, not after it.

What to ask:

• "Walk me through your development process for a GxP project from sprint 1 to deployment"

• "When do you start writing validation documentation?"

• "How do you handle deviations discovered during OQ?"

If the answer to the first question describes a waterfall process (requirements → build → validate → deploy), expect 6-12 months. If the answer describes sprint-integrated validation (requirements + build + validate in each sprint), expect 12-16 weeks.

Red flags to watch for

According to the ISPE GAMP 5 Good Practice Guide, the most common cause of validation failures is inadequate supplier assessment before project start. Sixty-two percent of regulated software projects that miss their validation deadline do so because the development partner lacked experience with the specific compliance framework required.

"We'll handle compliance at the end." This is the most expensive sentence in pharma software development. Compliance retrofitting costs 3-4x more than compliance by design.

"Our cloud provider is GxP-compliant." AWS, Azure, and GCP provide infrastructure compliance (SOC 2, ISO 27001). Your application layer must implement its own GxP controls. A partner who confuses infrastructure compliance with application compliance doesn't understand the requirement.

"We've worked with pharma companies before." Dig deeper. Building a pharma company's website is different from building their validated QMS. Ask specifically about validated systems and regulatory audits.

No mention of change control in the post-launch proposal. If the maintenance and support proposal doesn't explicitly address change control processes for a validated system, the partner doesn't understand what happens after launch. Post-launch modifications to a GxP system require documented impact assessment, approval, implementation, and re-validation without exception.

Unwillingness to share documentation samples. A partner with genuine GxP experience will have anonymized validation documentation samples ready for prospective clients. Reluctance to share samples suggests the documentation doesn't exist.

The bottom line

Choosing the wrong pharma software development partner doesn't just cost money - it costs time, regulatory credibility, and the opportunity cost of delayed digital capabilities. The pharma companies that get this decision right ship validated software in 12-16 weeks and build digital capabilities that compound over time. The ones that get it wrong spend 6-12 months on their first project and are reluctant to start the second.

If you're evaluating partners for a pharma software project, RaftLabs can show you what compliance-first development looks like - including the validation documentation, the timeline, and the engineering approach that makes it possible.